Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Marketing Status Prescription; Discontinued
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 68071-3093; 54288-140; 65862-538; 63415-0056; 68382-989; 17478-106; 70518-0932; 69097-282; 43063-457; 0143-9722; 61919-704; 80425-0076; 63187-384; 63323-355; 68083-415; 55111-279; 55150-156; 71335-0965; 67296-0897; 0904-6351; 70518-0968; 0781-5792; 67296-0972; 55154-5897; 42571-168; 51407-429; 50090-4572; 71335-0593; 63629-8070; 53002-3350; 68071-4512; 63187-514; 69097-289; 52343-120; 13668-083; 52343-121; 67296-1641; 55150-157; 0781-5791; 36000-295; 80425-0007; 68071-4926; 55111-281; 71205-234; 50090-1228; 65977-0039; 50090-2001; 67296-0975; 53002-2350; 55154-5898; 36000-294; 44567-436; 0143-9720; 44567-437; 63187-003; 68071-2074; 0143-9316; 68071-1860; 63187-833; 69097-287; 53002-2582; 53104-7550; 55111-280; 43063-637; 36000-048; 50383-286; 68071-4874; 68071-3166; 68180-241; 43063-459; 58118-1022; 68071-4726; 25021-132; 71335-0327; 71335-0133; 68071-4875; 67296-0977; 42708-122; 43063-638; 51407-430; 68180-242; 0527-1948; 0143-9721; 63187-925; 53069-0600; 68083-414; 71335-0391; 67296-1393; 50090-4797; 63187-004; 71335-0794; 68083-395; 50090-2498; 68071-3236; 71335-0434; 65841-692; 67296-1351; 71335-0380; 70934-094; 72578-098; 68071-4738; 43235-0007; 65841-691; 36000-296; 68071-3218; 63629-7681; 63187-438; 67296-0985; 31722-723; 65862-488; 65862-536; 54348-611; 50090-3214; 67296-1535; 72578-099; 0143-9317; 66721-200; 70518-2249; 61919-440; 43063-796; 53002-1350; 70934-050; 68788-6938; 0409-0528; 33342-023; 0781-5790; 67296-0744; 72578-100; 65841-693; 17478-107; 51407-428; 68083-416; 50090-4573; 49587-102; 68071-4900; 31722-722; 13668-084; 63629-4843; 61919-426; 65862-537; 70518-0453; 71205-002; 13668-082; 67296-1400; 68788-6816; 71335-0525; 80425-0009; 50090-4928; 70934-392; 67296-1546; 70771-1079; 52343-119; 45865-758; 36000-046; 44567-435; 55700-729; 0904-6353; 61919-987; 71335-1277; 31722-721; 68083-394; 68180-240; 67296-1325; 80425-0008; 72189-338; 36000-045; 67296-0998; 70518-2145; 71205-058; 72789-085; 80425-0077; 33342-022; 53002-1391; 0904-6352; 55525-0001; 36000-047; 71335-1208; 0143-9315; 33342-021
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Trichiasis23.02.06.011; 06.06.04.0230.000173%Not Available
Mitochondrial cytopathy14.11.02.0080.000173%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.05.02.016; 10.02.02.0230.000173%Not Available
Allergic cough22.02.03.011; 10.01.03.0400.000347%Not Available
Stenotrophomonas infection11.02.01.0490.000045%Not Available
Clostridium difficile infection11.02.02.0090.000780%Not Available
Graft infection12.02.09.026; 11.01.08.0530.000113%Not Available
Lymphomatoid papulosis23.03.08.0110.000520%Not Available
Tenosynovitis stenosans15.04.02.0050.000433%Not Available
Palatal oedema07.05.04.0080.001300%Not Available
Cell death14.11.02.005; 08.03.03.0030.000260%Not Available
Anticonvulsant drug level decreased13.17.01.0240.000347%Not Available
Multi-organ disorder08.01.03.0740.000045%Not Available
Ballismus17.01.02.0170.000953%Not Available
Sopor19.02.04.002; 17.02.04.021--Not Available
Candida endophthalmitis11.03.03.022; 06.04.05.0240.000136%Not Available
Sensory level abnormal13.07.03.0160.000433%Not Available
Myasthenia gravis crisis17.05.04.007; 15.05.08.004; 10.04.05.0070.000173%Not Available
Pruritus allergic10.01.03.046; 23.03.12.0100.000173%Not Available
Dysbacteriosis12.02.05.047; 07.11.01.0230.000260%Not Available
Myosclerosis15.05.03.0320.000780%Not Available
Enterocolitis bacterial11.02.01.038; 07.19.01.0210.000347%Not Available
Medial tibial stress syndrome15.02.04.0360.000260%Not Available
Inflammatory pain08.01.08.0280.000173%Not Available
Ligament rupture15.07.02.008; 12.01.07.0140.000433%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000347%Not Available
Mycobacterium ulcerans infection23.07.03.019; 11.04.02.0070.000173%Not Available
Cerebral calcification17.11.01.0120.000173%Not Available
Fear of death19.06.03.0060.000173%Not Available
Weight bearing difficulty15.03.01.0270.000433%Not Available
The 29th Page    First    Pre   29 30    Next   Last    Total 30 Pages